Invion Ltd Asset Resilience Ratio
Invion Ltd asset resilience ratio. Invion Ltd (IVX) has an Asset Resilience Ratio of 8.96% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IVX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Invion Ltd (2002–2022)
Asset resilience ratio of Invion Ltd from 2002 to 2022. This chart shows how Invion Ltd's Asset Resilience Ratio has changed over time. Read Invion Ltd (IVX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Invion Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IVX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$850.37K | 8.96% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$850.37K | 8.96% |
Asset Resilience Insights
- Limited Liquidity: Invion Ltd maintains only 8.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Invion Ltd Industry Peers by Asset Resilience Ratio
Compare Invion Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Invion Ltd Asset Resilience Ratio by Year (2002–2022)
Invion Ltd asset resilience ratio by year from 2002 to 2022. The table below shows the annual Asset Resilience Ratio data for Invion Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 42.28% | AU$8.47 Million ≈ $6.00 Million |
AU$20.04 Million ≈ $14.18 Million |
+23.90pp |
| 2021-06-30 | 18.38% | AU$1.04 Million ≈ $733.62K |
AU$5.64 Million ≈ $3.99 Million |
+2.59pp |
| 2017-06-30 | 15.79% | AU$917.49K ≈ $649.18K |
AU$5.81 Million ≈ $4.11 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$11.98 Million ≈ $8.48 Million |
-- |
| 2007-06-30 | 42.43% | AU$1.58 Million ≈ $1.12 Million |
AU$3.74 Million ≈ $2.64 Million |
-29.52pp |
| 2002-06-30 | 71.95% | AU$1.07 Million ≈ $754.97K |
AU$1.48 Million ≈ $1.05 Million |
-- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more